Kraig Biocraft Laboratories, Inc. Cash Flow Statement
KBLB|8 years of annual SEC 10-K data (FY2012-FY2019)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Kraig Biocraft Laboratories, Inc. used $1M in operating cash flow and negative free cash flow of $1M in FY2019.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -50.01 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$2.9M | -$1.2M | -$2.3M | -$3.1M | -$2.1M | -$1.9M | -$7.5M | -$1.6M |
| Depreciation & Amortization | - | $26.6K | $20.3K | $17.0K | $15.4K | $7.2K | $5.9K | $5.6K |
| Operating Cash Flow | -$1.1M | -$235.0K | -$729.5K | -$1.0M | -$967.6K | -$904.6K | -$800.2K | -$562.9K |
| Capital Expenditures | $100.8K | $11.4K | $31.2K | $2.5K | $39.3K | $41.8K | $3.5K | $0 |
| Free Cash Flow | -$1.2M | -$246.5K | -$760.7K | -$1.0M | -$1.0M | -$946.4K | -$803.6K | -$562.9K |
| FCF Margin | - | -61.4% | -781.7% | -3183.9% | - | - | - | - |